Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Glioblastoma 3Breast Neoplasms 3Brain Neoplasms 3Recurrence 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Gliosarcoma 2Breast Neoplasms, Male 2Squamous Cell Carcinoma of Head and Neck 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Inflammatory Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Fulvestrant 3Everolimus 3Cetuximab 3PX-866 2Alpelisib 2venetoclax 1tivozanib 1tipifarnib 1serabelisib 1sapanisertib 1ribociclib 1pembrolizumab 1palbociclib 1neratinib 1exemestane 1cemiplimab 1abemaciclib 1Trimetazidine 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Docetaxel 1Capecitabine 1CB-839 1CA-4948 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hereditary Sensory and Autonomic Neuropathies × tipifarnib × Clear all
NCT04997902 2025-12-23

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡